Literature DB >> 21632676

Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease.

Rodolfo Pérez Alamino1, José A Maldonado Cocco, Gustavo Citera, Pablo Arturi, Janitzia Vazquez-Mellado, Percival D Sampaio-Barros, Diana Flores, Rubén Burgos-Vargas, Helena Santos, José E Chavez-Corrales, Daniel Palleiro, Miguel A Gutierrez, Elsa Vieira-Sousa, Fernando M Pimentel-Santos, Sergio Paira, Alberto Berman, Mario Moreno-Alvarez, Eduardo Collantes-Estevez.   

Abstract

OBJECTIVE: To describe differential characteristics of axial involvement in ankylosing spondylitis (AS) as compared with that seen in psoriatic arthritis (PsA) and inflammatory bowel disease (IBD) in a cohort of Ibero-American patients.
METHODS: This study included 2044 consecutive patients with spondyloarthritis (SpA; ESSG criteria). Demographic, clinical, disease activity, functional ability, quality of life, work status, radiologic, and therapeutic data were evaluated and collected by RESPONDIA members from different Ibero-American countries between June and December 2006. Patients selected for analysis met modified New York criteria (mNY) for AS.
RESULTS: A total of 1264 patients met the New York criteria for AS: 1072 had primary AS, 147 had psoriatic, and 45 had IBD-associated spondylitis. Median disease duration was comparable among the 3 patient groups. Patients with primary AS were significantly younger (p = 0.01) and presented a higher frequency of males (p = 0.01) than the other 2 groups. Axial manifestations such as inflammatory back pain and sacroiliac pain were significantly more frequent in patients with primary AS (p = 0.05) versus other groups, whereas frequency of dactylitis, enthesitis, and peripheral arthritis was more common in patients with psoriatic spondylitis (p = 0.05). Spinal mobility was significantly more limited in patients with primary AS versus the other 2 groups (p = 0.0001). Radiologic changes according to BASRI total score were equally significant in primary AS. Disease activity (BASDAI), functional ability (BASFI), and quality of life (ASQoL) scores were comparable in the 3 groups.
CONCLUSION: Patients with primary AS had more severe axial involvement than those with spondylitis associated with psoriasis or IBD. Functional capacity, disease activity, and quality of life were comparable among the groups studied.

Entities:  

Mesh:

Year:  2011        PMID: 21632676     DOI: 10.3899/jrheum.101049

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis.

Authors:  Gamze Kılıç; Erkan Kılıç; Kemal Nas; Murat Karkucak; Erhan Çapkın; Abdullah Zübeyir Dağlı; Remzi Çevik; Salih Özgöçmen
Journal:  Clin Rheumatol       Date:  2014-07-02       Impact factor: 2.980

Review 2.  Seronegative arthritis in Latin America: a current review.

Authors:  Carla Gonçalves Schain Saad; Célio Roberto Gonçalves; Percival D Sampaio-Barros
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

Review 3.  Looking into the new ASAS classification criteria for axial spondyloarthritis through the other side of the glass.

Authors:  Nurullah Akkoc; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

Review 4.  Making the next steps in psoriatic arthritis management: current status and future directions.

Authors:  Diviya Sritheran; Ying Ying Leung
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

5.  American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip van den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan
Journal:  Arthritis Rheumatol       Date:  2015-09-24       Impact factor: 10.995

Review 6.  Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Authors:  Ennio Lubrano; Antonio Spadaro
Journal:  Clin Rheumatol       Date:  2012-05-03       Impact factor: 2.980

7.  Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?

Authors:  Siddharth Bethi; Abhijit Dasgupta; Michael H Weisman; Thomas J Learch; Lianne S Gensler; John C Davis; John D Reveille; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

Review 8.  Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology.

Authors:  Rodolfo Perez-Alamino; Hernan Maldonado-Ficco; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2015-11-17       Impact factor: 2.980

Review 9.  ASAS classification criteria for axial spondyloarthritis: time to modify.

Authors:  Nurullah Akkoc; Muhammad A Khan
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

10.  American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip Van Den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-09-24       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.